关于 2024 年度拟不进行利润分配的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、2024 年度利润分配预案的审议程序 武汉海特生物制药股份有限公司（以下简称"公司"）于 2025 年 4 月 17 日召开第九届董事会第二次会议、第九届监事会第二次会议，审议通过了《关于 <2024 年度利润分配预案>的议案》，该议案尚需提交 2024 年年度股东大会审议。 二、2024 年度利润分配预案的基本情况 经中审众环会计师事务所（特殊普通合伙）审计，公司 2024 年度合并报表 实现归属于上市公司股东的净利润为人民币-69,348,658.66 元，其中母公司实 现净利润为人民币 6,155,075.98 元。截至 2024 年 12 月 31 日，公司合并报表累 计 未 分配利润为 370,096,650.61 元，其中母公司累计 未 分配利润为 391,670,871.37 元。 证券代码：300683 证券简称：海特生物 公告编号：2025-020 武汉海特生物制药股份有限公司 （二）不触及其他风险警示情形的具体原因 根据《深圳证券交易所创业板股票 ...

Financial Performance - The company reported a significant loss due to intensified market competition and insufficient orders in the raw materials and intermediates business, leading to a revenue shortfall[6]. - The company incurred inventory impairment losses of approximately 10 million yuan due to reduced sales prices and high fixed asset depreciation costs in its subsidiaries[6]. - Non-operating income for the reporting period was approximately 35 million yuan, primarily from investment income and government subsidies, with government subsidies accounting for about 28 million yuan[6]. - The company plans to not distribute cash dividends or issue bonus shares for the reporting period[9]. - The company's operating revenue for 2024 was ¥648,974,123.98, representing a 7.75% increase compared to ¥602,284,306.91 in 2023[23]. - The net profit attributable to shareholders for 2024 was -¥69,348,658.66, an improvement of 42.60% from -¥120,822,819.73 in 2023[23]. - The net cash flow from operating activities increased significantly by 326.89% to ¥22,685,841.71 in 2024, compared to ¥5,314,257.07 in 2023[23]. - The total assets at the end of 2024 were ¥2,936,633,525.41, a decrease of 1.17% from ¥2,971,251,156.62 at the end of 2023[23]. - The company's basic earnings per share improved to -¥0.53 in 2024 from -¥0.93 in 2023, reflecting a 43.01% increase[23]. - The company reported a significant reduction in net profit attributable to shareholders after deducting non-recurring gains and losses, amounting to -¥103,726,470.25 in 2024, down from -¥146,323,982.19 in 2023, a decrease of 29.11%[23]. - The weighted average return on equity improved to -2.84% in 2024 from -4.85% in 2023, indicating a positive trend[23]. - The company received government subsidies amounting to ¥28,537,142.09 in 2024, compared to ¥12,766,083.34 in 2023, reflecting a significant increase in support[29]. Market and Industry Outlook - The global biopharmaceutical market is projected to grow from $36.38 billion in 2022 to $78.32 billion by 2030, with a compound annual growth rate (CAGR) of approximately 10.1%[32]. - The Chinese biopharmaceutical market is expected to grow from $66.5 billion in 2023 to $162.8 billion by 2030, with a CAGR of about 13.64%[33]. - The global CRO market is projected to grow from approximately $82.11 billion in 2023 to $106.45 billion by 2026, with a compound annual growth rate (CAGR) of about 9%[36]. - The Chinese CRO market is expected to expand from approximately 84.82 billion RMB in 2023 to 112.65 billion RMB by 2026, with a CAGR of around 10%[36]. - The market size for mouse nerve growth factor in China peaked at approximately 3.3 billion RMB in 2016, but has since declined due to policy impacts, particularly after its removal from the national medical insurance directory in 2019[34]. Business Operations and Services - The company continues to provide CRO, CMO, and CDMO services to domestic and international pharmaceutical companies, indicating a stable operational environment[8]. - The company has not experienced overcapacity or technological decline in its industry, suggesting a favorable market outlook[8]. - The company provides a comprehensive range of services including CRO, CMO, and CDMO, covering the entire value chain from drug development to clinical services and production[37]. - The company’s subsidiary, Tianjin Hankan, provides integrated CRO-CDMO services, covering the entire value chain from drug research to commercialization[50]. - The company’s subsidiary, Jingmen Hanrui, has over 102 multifunctional workshops and 103 antiviral workshops that have begun commercial production[52]. - The company offers raw material drug development, quality analysis, and stability research services, enhancing drug safety and quality[53]. - The CRO clinical services include I to IV phase clinical trial technical services, data management, and statistical analysis, ensuring comprehensive support for clinical research[54]. - The company has established a clinical trial institution data archive, facilitating the selection of qualified research units for clinical studies[55]. - The company is expanding its business scope from pharmaceutical R&D outsourcing to Contract Development and Manufacturing Organization (CDMO) services, providing integrated R&D and production services from preclinical to commercialization[56]. Research and Development - The company focuses on independent R&D, continuously promoting technological innovation and the development of new products[58]. - The company has established over 10 advanced formulation and raw material development platforms, enabling it to support more than 200 projects simultaneously[38]. - The company is engaged in independent research of small molecule chemical drugs, aiming to obtain clinical and production approvals for new products[72]. - The company is developing technical platforms for oral sustained-release formulations and injectable drug development to improve project quality and success rates[73]. - The company achieved dual-driven growth, with major products including Jinlujie and Epanemide contributing to performance and enhancing core competitiveness[74]. - The company has multiple small molecule generic drugs and active pharmaceutical ingredients under development, with progress reported as smooth[74]. - The company received NMPA approval for several new products, including Jinlujie eye drops and various generic drugs, expected to enrich the product pipeline[74]. - The company is actively pursuing the development of new indications for CPT in treating multiple myeloma and solid tumors[124]. - The company is committed to enhancing its R&D capabilities and optimizing project selection to mitigate risks associated with new drug development[136]. Governance and Compliance - The company’s financial report has been confirmed as true, accurate, and complete by its board of directors and management[5]. - The company has implemented a rigorous internal control system to monitor the compliance of fundraising activities[112]. - The company has established a dedicated bank account for the management of raised funds, ensuring proper tracking and usage of the funds[112]. - The audit department conducts quarterly checks on the usage of raised funds and reports findings to the audit committee[112]. - The company is committed to adhering to regulations regarding the management and use of raised funds as per relevant laws and guidelines[112]. - The company has a clear governance structure with independent directors and a diverse management team[159]. - The company maintains independence from its controlling shareholder in business, assets, personnel, and financial aspects[154]. - The company has an independent financial department with a sound financial management system, ensuring independent financial decision-making[156]. - The company emphasizes transparency in information disclosure, ensuring all shareholders receive fair access to relevant information[153]. - The company has established specialized committees within the board, including audit and remuneration committees, to enhance governance[147]. Employee and Talent Management - The company has a strong leadership team with diverse backgrounds in finance and management[162]. - The total number of employees at the end of the reporting period is 1,309, with 284 in the parent company and 1,025 in major subsidiaries[186]. - The employee composition includes 766 technical personnel, 318 production staff, and 90 sales personnel, reflecting a strong emphasis on technical expertise[186]. - The company has a clear cash dividend policy that aligns with its articles of association and shareholder resolutions[191]. - The company plans to continue leveraging its compensation and benefits system to enhance employee motivation and reduce turnover in 2025[188]. - The company has no outsourced labor arrangements, indicating a focus on in-house talent management[190]. - The company implemented a salary increase covering 45% of employees in 2022, and all employees received timely salary payments, holiday subsidies, performance bonuses, and year-end bonuses in 2024[188]. - In 2024, the company conducted over 230 GMP-related training sessions, focusing on biopharmaceutical content to enhance employees' theoretical knowledge and operational skills[189]. Strategic Initiatives and Future Plans - The company plans to enhance R&D investment, focusing on innovative drug development and expanding its drug pipeline[124]. - The company aims to create optimal innovative drugs through a dual-driven approach of R&D and market expansion[76]. - The company is exploring strategic acquisitions to bolster its portfolio, with potential targets identified in the biotechnology sector[170]. - The company is actively monitoring national policies and market conditions to mitigate risks associated with its fundraising projects[135]. - The company aims to expand its R&D pipeline through strategic collaborations and technology transfers to accelerate project progress[136]. - The company is focusing on expanding its market presence and enhancing its product offerings[162]. - The company is committed to maintaining high standards in corporate governance and management practices[160]. - The company is actively participating in industry associations to promote its interests and innovations[162].

Financial Performance - The company's revenue for Q1 2025 was ¥156,670,309, representing an increase of 18.79% compared to ¥131,887,548 in the same period last year[5] - The net loss attributable to shareholders was ¥13,930,370, a 15.81% improvement from a loss of ¥16,545,525 in the previous year[5] - The net profit for the current period was a loss of ¥14,417,854.71, an improvement compared to a loss of ¥17,491,671.96 in the previous period, indicating a reduction in losses of approximately 17.5%[24] - Basic earnings per share for the current period was -¥0.11, compared to -¥0.13 in the previous period, showing an improvement in earnings per share[25] Cash Flow and Liquidity - The net cash flow from operating activities was negative at ¥49,792,802, a significant decline of 644.52% compared to a positive cash flow of ¥9,144,316 in the same period last year[5] - Operating cash flow for the period was -$49.79 million, a significant decrease from $9.14 million in the previous period, indicating a decline in operational efficiency[26] - The ending cash and cash equivalents balance was $160.74 million, down from $463.24 million, highlighting a significant liquidity reduction[27] - Total cash inflow from operating activities was $124.15 million, a decrease from $189.81 million, reflecting challenges in core business operations[26] Assets and Liabilities - The total assets decreased by 3.94% to ¥2,821,065,437 from ¥2,936,633,525 at the end of the previous year[5] - The total current assets decreased from ¥1,306,333,167.96 to ¥1,198,932,206.75, a reduction of about 8.3%[20] - The company's cash and cash equivalents decreased from ¥419,151,366.14 to ¥160,772,770.92, a decline of approximately 61.7%[20] - Total liabilities decreased to ¥423,896,092.27 from ¥525,046,325.88, a reduction of approximately 19.3%[22] Operating Costs and Expenses - Total operating costs decreased to ¥172,864,987.49 from ¥185,592,842.22, a reduction of about 6.2%[23] - The management expenses decreased by 51.71% to ¥23,870,424.25, primarily due to changes in inventory write-offs from the previous year[9] - Research and development expenses for the current period were ¥27,012,145.01, slightly down from ¥27,937,527.55 in the previous period[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 10,175[12] - The largest shareholder, Wuhan Sanjiangyuan Investment Development Co., Ltd., holds 25,209,424 shares, accounting for 19.26% of total shares[12] - The total number of shares held by the top 10 shareholders includes significant stakes from both institutional and individual investors, with the top two shareholders holding a combined 30.56%[12] Investment and Financing Activities - Cash inflow from investment activities totaled $200.92 million, up from $173.42 million in the previous period, reflecting increased investment recovery[27] - Cash outflow for investments reached $389.20 million, compared to $224.68 million previously, indicating a substantial increase in capital expenditures[27] - Net cash flow from financing activities was -$20.30 million, worsening from -$4.80 million in the prior period, suggesting increased financial strain[27] Other Notable Points - The company reported a government subsidy of ¥2,050,978.94, contributing to its non-recurring gains[6] - The company experienced a 1063.38% increase in other operating income, reaching ¥43,579.07, attributed to a rise in non-recurring income[9] - The company has not disclosed any new product developments or market expansion strategies in the current reporting period[16] - The company did not undergo an audit for the first quarter report, which may affect stakeholder confidence in financial reporting[28]

一、股东股份质押基本情况 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 武汉海特生物制药股份有限公司（以下简称"公司"）于近日收到公司控股股东武汉三江源投资发展有限 公司（以下简称"三江源"）的通知，获悉三江源将其持有的公司部分股份办理了质押及解除质押手续， 具体事项如下： （一）股东股份质押及解除质押的基本情况 1、股东股份质押情况 ■ 2、股东股份解除质押情况 ■ 3、股东股份累计质押情况 截至本公告披露日，三江源及其一致行动人所持质押股份情况如下： ■ 二、其他说明 1、本次股份质押式回购交易事项不会对上市公司生产经营、公司治理、业绩补偿义务履行等产生实质 性影响。 2、公司控股股东三江源资信状况良好，具备资金偿还能力，股份质押式回购交易产生的相关风险在可 控范围内，不会导致公司实际控制权的变更，其所持有的股份目前不存在平仓风险。 3、三江源不存在非经营性资金占用、违规担保等侵害上市公司利益的情形。 4、公司将持续关注其质押情况及质押风险情况，并按照有关规定及时履行信息披露义务,敬请广大投资 者注意投资 ...

证券代码：300683 证券简称：海特生物 公告编号：2025-007 武汉海特生物制药股份有限公司 关于控股股东部分股份质押及解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股东股份质押基本情况 武汉海特生物制药股份有限公司（以下简称"公司"）于近日收到公司控股 股东武汉三江源投资发展有限公司（以下简称"三江源"）的通知，获悉三江源 将其持有的公司部分股份办理了质押及解除质押手续，具体事项如下： （一）股东股份质押及解除质押的基本情况 1、股东股份质押情况 | | 是否为控 股股东或 | 本次质押 | 占其所持 | 占公司 | 是否为 | 是否为 | 质押起 | 质押 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名称 | 第一大股 | | | 总股本 | | 补充质 | | | 质权人 | 质押用途 | | | 东及其一 | 数量(股） | 股份比例 | 比例 | 限售股 | 押 | 始日 | 到期日 | | | | | 致行动 ...

武汉海特生物制药股份有限公司（以下简称"公司"）于 2019 年 12 月 23 日召开第七届董事会第八次会议和第七届监事会第八次会议，审议通过了《关于 参与投资设立产业投资基金的议案》，同意公司以自有资金认缴出资人民币 1,000 万元参与设立湖北青柠创业投资基金有限公司（以下简称"青柠基金"）。 具体内容详见公司于 2019 年 12 月 23 日披露于巨潮资讯网（www.cninfo.com.cn） 的《关于参与投资设立产业投资基金的公告》（公告编号 2019-056）。 2020 年 1 月 15 日，青柠基金完成工商设立登记手续，并取得宜都市市场监 督管理局颁发的《营业执照》。具体内容详见公司于 2020 年 1 月 15 日披露于巨 潮资讯网（http://www.cninfo.com.cn）的《关于参与投资设立产业投资基金的 进展公告》（公告编号：2020-003）。 2020 年 9 月 22 日，青柠基金按照《证券投资基金法》和《私募投资基金监 督管理暂行办法》等法律法规的要求在中国证券投资基金业协会完成了备案手续， 并取得了《私募投资基金备案证明》（备案编码：SLN955）。具体内容详见公 ...

证券代码：300683 证券简称：海特生物 公告编号：2025-005 武汉海特生物制药股份有限公司 关于使用闲置募集资金及自有资金购买理财产品的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 武汉海特生物制药股份有限公司（以下简称"公司"）于 2024 年 11 月 12 日召开第八届董事会第十九次会议、第八届监事会第十九次会议，会议审议通过 了《关于使用闲置募集资金及自有资金进行现金管理的议案》，同意公司在确保 不影响募集资金投资项目建设、不影响正常经营及确保资金安全的情况下，使用 不超过人民币 110,000 万元的资金购买投资期限不超过 12 个月，安全性高、流 动性好的低风险理财产品。其中，闲置募集资金的使用额度不超过人民币 45,000 万元，自有资金的使用额度不超过人民币 65,000 万元，本事项在董事会审议权 限内，无需提交股东大会审议，不构成关联交易。在上述额度内，资金可以滚动 使用，期限为 1 年。具体内容详见公司于 2024 年 11 月 12 日在巨潮资讯网（http： //www.cninfo.com.cn）披露的《关于使 ...

| 项目名称 | 2024 年度拟计提减值准备金额 | | --- | --- | | 1、信用减值损失 | -303.85 | | 应收账款坏账损失 | -303.85 | | 2、资产减值损失 | -1,066.85 | | 其中：存货跌价损失 | -814.34 | | 合同资产减值损失 | -252.51 | | 合计 | -1,370.70 | 证券代码：300683 证券简称：海特生物 公告编号：2025- 004 武汉海特生物制药股份有限公司 关于 2024年度拟计提资产减值准备的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在任何虚假 记载、误导性陈述或者重大遗漏。 一、 本次拟计提资产减值准备情况概述 根据《企业会计准则》及武汉海特生物制药股份有限公司（以下简称"公司" 、"本公司"）会计政策的相关规定，公司合并报表范围内各公司对2024年12月末 所属资产进行了减值测试，基于谨慎性原则，拟对可能发生资产减值损失的相关资 产计提减值准备，预计2024年全年计提资产减值准备金额合计为1370.70万元。具 体明细如下： 单位： 人民币万元 本次拟计提资产减值准备事项，符合《企业 ...

Financial Projections - The estimated net profit for 2024 is projected to be a loss of between 57 million and 78 million RMB, compared to a loss of 120.82 million RMB in 2023[3] - The estimated operating revenue for 2024 is projected to be between 577.6 million and 704.49 million RMB, down from 602.28 million RMB in 2023[3] - The estimated net profit after deducting non-recurring gains and losses is projected to be a loss of between 88 million and 120 million RMB, compared to a loss of 146.32 million RMB in 2023[3] Impairment and Losses - The company expects an impairment loss on inventory of approximately 8 million RMB due to lower sales prices and high fixed asset depreciation costs[6] - Non-recurring gains and losses are expected to impact net profit by approximately 31 million to 42 million RMB, primarily from investment income and government subsidies[6] Subsidiary and Business Challenges - The company has added a new consolidated subsidiary, Beijing Shadong Biotechnology Co., Ltd., which focuses on drug research and clinical trials, contributing to the overall net loss[5] - The company faces challenges in its raw materials and intermediates business due to intensified market competition and insufficient orders, leading to ongoing losses[5] Financial Data and Investor Advisory - The company has communicated with the accounting firm regarding the earnings forecast, and there are no discrepancies noted[4] - The financial data presented is preliminary and has not been audited by the accounting firm, with the final figures to be disclosed in the 2024 annual report[7] - Investors are advised to make cautious decisions and be aware of investment risks due to the preliminary nature of the financial data[7]

证券代码：300683 证券简称：海特生物 公告编号：2025-001 武汉海特生物制药股份有限公司 武汉海特生物制药股份有限公司（以下简称"公司"）2024 年前三季度权 益分派方案已获2024年12月26日召开的2024年第二次临时股东大会审议通过， 现将权益分派事宜公告如下： 一、股东大会审议通过利润分配方案情况 1、公司 2024 年第二次临时股东大会审议通过的 2024 年前三季度利润分配 预案为：以公司总股本 130,894,391 股为基数，向全体股东每 10 股派发现金股 利 1.30 元（含税），共计分配现金股利人民币 17,016,270.83 元（含税），本 次利润分配不转增股本，不送红股。 2、自公司 2024 年前三季度利润分配方案披露至实施期间，公司股本总额未 发生变化。公司目前未进行股份回购，没有股份回购专用账户；在本次利润分配 方案经公司董事会审议通过之日至公司权益分派实施公告确定的股权登记日前 如公司总股本发生变动的，公司维持分红总额不变的原则，相应调整每股现金分 红金额。 3.本次实施的权益分派方案与 2024 年第二次临时股东大会审议通过的利润 分配预案一致。 4.本次实 ...